<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1025-0255</journal-id>
<journal-title><![CDATA[Revista Archivo Médico de Camagüey]]></journal-title>
<abbrev-journal-title><![CDATA[Arch méd Camagüey]]></abbrev-journal-title>
<issn>1025-0255</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Ciencias Médicas de Camagüey]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1025-02552023000100016</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[La expresión del Ki67 y su correlación con factores pronósticos clásicos del carcinoma mamario]]></article-title>
<article-title xml:lang="en"><![CDATA[The expression of Ki67 and its correlation with classic prognostic value factors]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Pérez]]></surname>
<given-names><![CDATA[Raisel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Llanes-García]]></surname>
<given-names><![CDATA[Llanuris]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Agüero-Arboláez]]></surname>
<given-names><![CDATA[María del Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Borrego-Gutiérrez]]></surname>
<given-names><![CDATA[Disney]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguado-Besú]]></surname>
<given-names><![CDATA[Yunexy]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alfonso-González]]></surname>
<given-names><![CDATA[Carmen Patricia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Ciencias Médicas Facultad de Medicina Departamento de Ciencias Básicas Biomédicas Morfológicas]]></institution>
<addr-line><![CDATA[Villa Clara ]]></addr-line>
<country>Cuba</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Ciencias Médicas Hospital Clínico-Quirúrgico Docente Celestino Hernández Robau Departamento de Anatomía Patológica]]></institution>
<addr-line><![CDATA[Villa Clara ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<volume>27</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1025-02552023000100016&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1025-02552023000100016&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1025-02552023000100016&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: El Ki67 es una proteína reguladora del ciclo celular asociada a la proliferación de las células tumorales. Su expresión siempre ha tenido un papel en la clasificación tumoral, constituye uno de los factores pronósticos y predictivos en el carcinoma mamario.  Objetivo: Determinar la relación entre la expresión del marcador de Ki67 y otros factores pronósticos clásicos del cáncer de mama.  Métodos: Se realizó un estudio descriptivo analítico, de corte transversal, realizado en el Hospital Clínico-Quirúrgico Docente Celestino Hernández, Villa Clara, entre enero 2017 y mayo de 2019. Se incluyeron 286 mujeres con diagnóstico de carcinoma de mama infiltrante, a cuyas biopsias se les realizó estudio inmunohistoquímico. La expresión del marcador celular Ki67 fue categorizado como baja (Ki67&lt;20 %) y alta (Ki67&gt;20 %). Se analizó la relación entre el nivel de expresión de Ki67 con otros factores pronósticos y predictivos del carcinoma mamario.  Resultados: El tipo histológico no especial (carcinoma ductal) fue el que se reportó con mayor frecuencia. Los niveles de expresión altos del marcador celular Ki67 (Ki67&#8805;20 %) se asociaron con el grado histológico alto (grado 3) y la sobreexpresión de Her2. La expresión baja del Ki-67 (&lt;20 %) se asoció con la expresión de los receptores de estrógeno y progesterona. No se demostró asociación significativa entre la talla tumoral y la expresión de Ki67.  Conclusiones: Los niveles de expresión del Ki67 mostraron una asociación significativa con varios factores predictivos y pronósticos clásicos del cáncer de mama.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Ki67 is a regulatory protein of cellular cycle which is associated to the proliferation of tumoral cells. Its expression has always had an important role at the tumor classification and it is one of the prognostic and predictive factors in breast carcinoma.  Objective:  To determine the relationship between the expression of Ki67 and other classic prognostic factors used in breast cancer.  Methods: A cross-sectional, analytic and descriptive study was carried out at the Teaching Clinic-Surgical Hospital Celestino Hernández, Villa Clara, from January 2017 to June 2019. It was included 286 women with diagnosis of infiltrating breast carcinoma, whose biopsies were studied by immunohistochemistry. The Ki-67 cell marker expression was categorized as low (Ki-67&lt;20 %) and high (Ki-67&gt;20 %). It was analyzed the relationship between level of expression of Ki67 and other classical prognostic and predictive factors.  Results: The no special histological type (ductal carcinoma) was the type more often reported. High expression level of Ki67 was associated with the high histological grade (grade 3) and the overexpression of Her2. Low expression of Ki-67 (&lt;20 %) was associated with the expression of estrogen and progesterone receptors. There was not significant association between the tumor size and the expression of Ki67.  Conclusions: The levels of expression of Ki67 showed significant association with several predictive and prognostic factors of breast carcinoma.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[NEOPLASIAS DE LA MAMA]]></kwd>
<kwd lng="es"><![CDATA[PRONÓSTICO]]></kwd>
<kwd lng="es"><![CDATA[ANTÍGENO KI-67]]></kwd>
<kwd lng="es"><![CDATA[PROLIFERACIÓN CELULAR]]></kwd>
<kwd lng="es"><![CDATA[CORRELACIÓN DE DATOS]]></kwd>
<kwd lng="en"><![CDATA[KI67]]></kwd>
<kwd lng="en"><![CDATA[CELLULAR PROLIFERATION]]></kwd>
<kwd lng="en"><![CDATA[PROGNOSTIC FACTORS]]></kwd>
<kwd lng="en"><![CDATA[IMMUNOHISTOCHEMISTRY STUDY]]></kwd>
<kwd lng="en"><![CDATA[BREAST CANCER]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valle-Solís]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Miranda-Aguirre]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Mora-Pérez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pineda-Juárez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Gallardo-Valencia]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Santana]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Supervivencia en cáncer de mama por subtipo mediante inmunohistoquímica: Un estudio retrospectivo]]></article-title>
<source><![CDATA[Gac Med Mex]]></source>
<year>2019</year>
<volume>155</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S50-5</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez Navarro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Socorro Castro]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inmunohistoquímica en el cáncer de mama. Herramienta necesaria en la actualidad]]></article-title>
<source><![CDATA[Medisur]]></source>
<year>2018</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>209-13</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública</collab>
<source><![CDATA[Anuario Estadístico 2020]]></source>
<year>2021</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Dirección Nacional de Registros Médicos y Estadísticas de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Panal Cusati]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera de la Muela]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hardisson Hernaez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Choqueneira Dionisio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Román Guindo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[de Santiago García]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Correlación entre la expresión de Ki67 con factores clásicos pronósticos y predictivos en el cáncer de mama precoz]]></article-title>
<source><![CDATA[Rev Senol Patol Mamar]]></source>
<year>2014</year>
<volume>27</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>163-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<collab>Programa Argentino de Consensos de Enfermedades Oncológicas</collab>
<article-title xml:lang=""><![CDATA[Factores pronósticos y predictivos en cáncer de mama temprano. Consenso Nacional Inter-Sociedades]]></article-title>
<source><![CDATA[Revista Argentina de Mastología]]></source>
<year>2016</year>
<volume>36</volume>
<numero>128</numero>
<issue>128</issue>
<page-range>12-33</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[TO]]></given-names>
</name>
<name>
<surname><![CDATA[Leung]]></surname>
<given-names><![CDATA[SCY]]></given-names>
</name>
<name>
<surname><![CDATA[Rimm]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Dodson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Acs]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Badve]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of Ki67 in Breast Cancer: Undated Recommendations From the International Ki67 in Breast Cancer Working Group]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2021</year>
<volume>113</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>808-19</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mayanga Sausa]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Características clínico patológicas del cáncer de mama asociadas a la expresión del marcador celular Ki-67 en el Hospital Nacional Edgardo Rebagliati Martins, 2013-2017.]]></article-title>
<source><![CDATA[An Fac med]]></source>
<year>2019</year>
<volume>80</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>427-31</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[FY]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[HX]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic Value of Ki-67 in Breast Cancer Patients with Positive Axillary Lymph Nodes: A Retrospective Cohort Study]]></article-title>
<source><![CDATA[PLoS ONE]]></source>
<year>2014</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mannell]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of Ki67 in breast cancer]]></article-title>
<source><![CDATA[S Afr j surg]]></source>
<year>2016</year>
<volume>54</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davey]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Hynes]]></surname>
<given-names><![CDATA[SO]]></given-names>
</name>
<name>
<surname><![CDATA[Kerin]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lowery]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ki67 as a Prognostic Biomarker in Invasive Breast Cancer]]></article-title>
<source><![CDATA[Cancers]]></source>
<year>2021</year>
<volume>13</volume>
<numero>17</numero>
<issue>17</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Untch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gerber]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Harbeck]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Jackisch]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Marschner]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Möbus]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[13th St. Gallen International Breast Cancer Conference 2013: Primary Therapy of Early Breast Cancer Evidence, Controversies, Consensus- Opinion of a German Team of Experts (Zurich 2013)]]></article-title>
<source><![CDATA[Breast Care]]></source>
<year>2013</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>221-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coates]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Winer]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Goldhirsch]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gelber]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Gnant]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Piccart-Gebhart]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2015</year>
<volume>26</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1533-46</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cserni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Histological type and typing of breast carcinomas and they WHO classification changes over time]]></article-title>
<source><![CDATA[Pathologica]]></source>
<year>2020</year>
<volume>112</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-41</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alcaide Lucena]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez González]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[de Reyes Lartategui]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gallart Aragón]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Barrón]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[García Rubio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clasificación actual del cáncer de mama. Implicación en el tratamiento y pronóstico de la enfermedad]]></article-title>
<source><![CDATA[Cir Andal]]></source>
<year>2021</year>
<volume>32</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>155-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Abbas]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Aster]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Robbins Basic Pathology]]></source>
<year>2013</year>
<edition>9th</edition>
<publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aman]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Doukoure]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Koffi]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Koui]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Traore]]></surname>
<given-names><![CDATA[ZC]]></given-names>
</name>
<name>
<surname><![CDATA[Kouyate]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Her2 overexpression and correlation with other significant clincopathologic parameters in Ivorian breast cancer women]]></article-title>
<source><![CDATA[BMC Clin Pathol]]></source>
<year>2019</year>
<volume>19</volume>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gamarra Manrique]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
</person-group>
<source><![CDATA[Evaluación de la sobre-expresión molecular del receptor HER2/neu (Human Epidermal Growth Factor Receptor 2/Neuro Glioblastoma) en cáncer de mama humano, mediante inmunohistoquímica por anticuerpos monoclonales, y su correlación pronóstica con el sistema de estadiaje TNM]]></source>
<year>2018</year>
<publisher-loc><![CDATA[Arequipa ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Nacional de San Agustín de Arequipa]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galve Agudo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Valor pronóstico y predictivo del índice de proliferación Ki67 en el carcinoma infiltrante de mama]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Zaragoza ]]></publisher-loc>
<publisher-name><![CDATA[Universidad de Zaragoza]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Breast cancer in 30-year-old or younger patients: clinicopathologic characteristic and prognosis]]></article-title>
<source><![CDATA[World J Surg Oncol]]></source>
<year>2015</year>
<volume>13</volume>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramírez-Torres]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Maycotte-González]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Rivas-Ruiz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación de la clasificación molecular por inmunohistoquímica en cáncer de mama avanzado tratado con epirubicina y docetaxel: diferencias clínicas, patológicas, terapéuticas y pronósticas]]></article-title>
<source><![CDATA[Gac Mex Oncol]]></source>
<year>2018</year>
<volume>17</volume>
<page-range>15-27</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez Sánchez]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
<name>
<surname><![CDATA[Vela Chávez]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Mora Tiscareño]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnóstico Histopatológico y Factores Pronóstico en Cáncer Infiltrante de Glándula Mamaria]]></article-title>
<source><![CDATA[Cancerología 3]]></source>
<year>2008</year>
<page-range>7-17</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Awadelkarim]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Mariani-Costantini]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Osman]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Barberis]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ki-67 Labeling Index in Primary Invasive Breast Cancer from Sudanese Patients: A Pilot Study]]></article-title>
<source><![CDATA[ISRN Pathology]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thangarajah]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Enninga]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Malter]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Hamacher]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Markiefka]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Richters]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Retrospective analysis of Ki-67 Index and its prognostic significance in over 800 primary breast cancer cases]]></article-title>
<source><![CDATA[Anticancer Res]]></source>
<year>2017</year>
<volume>37</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1957-64</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Makar]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Lasheen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of the Prognostic Role of Ki-67 and Optimal Cutoff Value in Early Breast Cancer: A Retrospective Analysis]]></article-title>
<source><![CDATA[Res Oncol]]></source>
<year>2020</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>35-41</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Larios León]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<source><![CDATA[El estado de los receptores hormonales como factor pronostico en pacientes con cáncer de mama HER2 positivos metastásicos recientemente diagnosticados en el Hospital Almanzor Aguinaga Asenjo durante el periodo 2016-2017]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Lambayeque ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Nacional Pedro Ruiz Gallo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kamranzadeh]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ardekani]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Kasaeian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sadighi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Maghsudi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jahanzad]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association between Ki-67 expression and clinicopathological features in prognosis of breast cancer: a retrospective cohort study]]></article-title>
<source><![CDATA[J Res Med Sci]]></source>
<year>2019</year>
<volume>24</volume>
<numero>30</numero>
<issue>30</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
